 |
|
LeadershipAdnexus is led by a leadership team with extensive industry experience covering all aspects of research, development, organizational development, partnering, and commercialization. Collectively, the team has previously played key roles in the development and commercialization of over 50 products.
John Edwards, President
Eric Furfine, Ph.D., Senior Vice President of Research and Preclinical Development
Kelledy Manson, Vice President, Product Development
Cliff Bechtold, Vice President, Strategic Operations
Sharon Cload, Ph.D., Vice President, Discovery
Ray Camphausen, Ph.D., Associate Vice President, Protein Design
Bruce Silver, M.D., Medical Director
Kathy Wilkinson, Director, Human Resources
Kathy Wilkinson brings over 15 years of Human Resources experience in the biotechnology and high-tech industries with a focus on developing HR strategies and programs that align with business objectives. Prior to joining Adnexus, Ms. Wilkinson was the Senior Director of Human Resources at Codon Devices, Inc. where she was responsible for the development of communication strategies, talent management programs, and cultural development. Before that, Ms. Wilkinson was the Director of Human Resources for Aspect Software where she led compensation strategy and design, oversaw the HR service center, and provided business partner support to multiple functions. Prior to Aspect, she held multiple HR generalist and management roles at software companies. Ms. Wilkinson has a Bachelors degree in Sociology from Harvard University. |
A Team That's Done ItCollectively, the Adnexus team has previously played key roles in the development and commercialization of over 50 products. |
John Edwards has served as President of Adnexus since 2007. He joined the recently formed company in 2004 as part of the senior management team, serving primarily as Chief Operating Officer. Mr. Edwards has 25 years of experience in discovery, development, and global commercialization of biopharmaceuticals, working at both start-up and established biotechnology companies, as well as two pharmaceutical companies. Prior to joining Adnexus, he served as Vice President of Sales, Marketing, and Medical Affairs at Transkaryotic Therapies. Additionally, during his 15-year tenure with Wyeth Pharmaceuticals/Genetics Institute, Mr. Edwards held senior-level positions in research and development, manufacturing, and commercial operations, during which time he built a $500 million global pharmaceutical business in hematology. He also held senior-level positions in U.S. and global marketing at Wyeth, where he successfully launched four products in three different therapeutic areas (hematology, oncology, and organ transplantation). Mr. Edwards received his M.B.A. from Boston University and his B.S. in Chemical Engineering from the University of Massachusetts, Amherst. 
Dr. Furfine has nearly 20 years of experience in drug research and development, and has been involved in advancing numerous products into clinical development across multiple therapeutic areas. Prior to joining Adnexus, he was Vice President of Preclinical Development at Regeneron Pharmaceuticals, where he led all aspects of preclinical development and a significant portion of clinical pharmacology. Dr. Furfine also spent over a decade in senior level research positions at GlaxoSmithKline where he was program leader and co-inventor of LEXIVA® (fosamprenavir calcium). Dr. Furfine conducted his postdoctoral research at University of California, San Francisco under Dr. C. C. Wang and received his Ph.D. from Brandeis University under the tutelage of Robert Abeles.
Ms. Manson joined Adnexus in 2007 as head of Program Management and currently serves as our Vice President of Product Development. Prior to Adnexus, she was a Program Executive and Sr. Director of Bioanalytical Chemistry at a Therion biologics, a privately held cancer vaccine company where she was responsible for leading the development of a first- in-class novel prostate cancer vaccine from early discovery through successful proof of concept Phase 2 clinical studies. In addition, she directed the bioanalytical assessment of Therion's entire cancer vaccine portfolio which included the preparation of a BLA for a Phase 3 pancreatic cancer vaccine. Ms Manson began her 16 year biopharmaceutical career at TSI Corporation and Genzyme Transgenics where she was Director of Immunology and managed a multi-million dollar global NIH contract to evaluate novel HIV vaccine strategies. Ms Manson has a BS in Medical Technology from Michigan State University and a Masters in Biology from Worcester Polytechnical Institute.
Mr. Bechtold has 18 years experience in the pharmaceutical industry, with particular expertise in advancing clinical programs through development to commercialization. Mr. Bechtold joined Bristol-Myers Squibb in 1991, where he held positions of increasing responsibility in a broad range of roles after starting his career as a Research Scientist. His most recent position was the Staff Director, Virology and Neuroscience Therapeutic Area Head. He has played a leadership role in many key initiatives, which included the development and commercialization of SPRYCEL® which was completed in record time. Mr. Bechtold began his career at BMS in the Virology Discovery Department later moving to Clinical Development in the area of Infectious Disease where he served as lead Clinical Scientist. He completed his undergraduate studies in Microbiology at South Dakota State University and holds a M.S. degree in Medical Microbiology from Creighton University School of Medicine. 
Dr. Cload has served as our Vice President, Discovery since July, 2008. She has more than a decade of experience in lead discovery and managing biotech-pharma partnerships. Prior to joining Adnexus, Dr. Cload spent seven years in lead discovery and technology development at Archemix Corp., most recently as Vice President, Aptamer Discovery. From 1996 to 2000, Dr. Cload developed small molecule discovery technologies for both RNA and protein targets at Anadys Pharmaceuticals (formerly Scriptgen Pharmaceuticals), a biotechnology company. Dr. Cload holds a Ph.D. in Bio-Organic chemistry from Yale University, and was an NIH post-doctoral fellow with Peter Schultz at the University of California, Berkeley. Dr. Cload received her BA in Chemistry at New College of the University of South Florida.
Dr. Camphausen has served as our Associate Vice President, Protein Design since June, 2008. Prior to that, he served with increasing levels of responsibility in our discovery and research group, including, most recently, as our Associate Vice President, Discovery from August 2006 to June 2008. Dr. Camphausen has more than 20 years of experience in the biotech industry. Prior to Adnexus, he served as Vice President, Research & Discovery at Thios Pharmaceuticals, Inc., a biotechnology start-up in California. Dr. Camphausen also spent 15 years at Wyeth Pharmaceuticals/Genetics Institute where he was the Associate Director and Project Leader for protein and small molecule antagonists directed toward cell adhesion molecules involved in inflammation and cardiovascular diseases. During his tenure at Wyeth Pharmaceuticals/Genetics Institute, Dr. Camphausen advanced four discovery programs to clinical development, and was also a founding member of the company's Carbohydrate Chemistry group. Dr. Camphausen has a B.A. from UC San Diego and a Ph.D. from Colorado State University.
Dr. Silver is a highly experienced oncologist and drug development expert. Prior to joining Adnexus, he was Vice President, Oncology Global Product Development Services at PRA International, a global contract research organization. Dr. Silver was also Chairman of the Department of Medicine at Calvert Memorial Hospital in Maryland and spent over 15 years in private practice in oncology, hematology and internal medicine. He served as a Principal Site Investigator for the National Surgical Adjuvant Breast and Bowel Project (NSABP) and for the Eastern Cooperative Oncology Group (ECOG). Dr. Silver received his M.D. from the University of Maryland Medical School and his B.S. from University of Maryland, both summa cum laude. He completed his residency at Johns Hopkins and held a Medical Oncology Fellowship at the National Institutes of Health. He is a board-certified internist and medical oncologist, a Fellow of the American College of Physicians, and a member of the American Society of Clinical Oncology.
